Abstract: Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.

Abstract: Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.

Abstract: Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Abstract: Described herein are tissues containing semiconductor nanomaterials. In some embodiments, the tissues include vascular cells, cardiomyocytes, and/or cardiac fibroblasts. The tissue may be scaffold-free. In some embodiments, the tissue includes an electrically conductive network. The tissue may exhibit synchronized electrical signal propagation within the tissue. In some embodiments, the tissue exhibits increased functional assembly of cardiac cells and/or increased cardiac specific functions compared to a cardiac tissue prepared using a conventional tissue culture method. Methods of preparing and using such tissues are also described herein.

Abstract: The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

Abstract: Embodiments concern methods and small molecule compositions for selectively inhibiting RAD51-mediated D-loop formation while preserving RAD51's ability to form nucleoprotein filaments. The selective RAD51 D-loop formation activity inhibitors DNA repair while minimizing replication-associated toxicity in normal tissue.

Abstract: Provided herein are methods for generating an estimated coagulation test result from an underfilled sample tube.

Abstract: Stable, macroscopic single-crystal chiral liquid crystal compositions are described. The compositions include a single-crystal chiral liquid crystal material on a patterned surface. The patterned surface seeds a particular crystallographic orientation at the substrate-liquid crystal interface. Also described are methods of forming the single-crystal chiral liquid crystal compositions.

Abstract: The present disclosure provides combinations of immunologic inhibitors for the treatment of cancer. In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7.

Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.

Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.

Abstract: This disclosure generally relates to a system for communicating data generated by a wearable device to one or more server devices for analysis. The one or more server devices may transmit activity level data, or a graphical representation thereof, for a wearer of a wearable device to a device associated with a healthcare provider. The activity level data may include one or more of an active minutes element, a television time element, a word count element, a sleep duration element and a reading duration and score element.

Abstract: Technologies for a long-lived 3D multimode microwave cavity are disclosed. In the illustrative embodiment, a series of overlapping holes are drilled into a monolithic block of aluminum forming a cavity. The dimensions of the cavity formed by the overlapping holes can be made long by drilling a long series of holes in a row and can be made high by drilling holes a certain depth into the cavity. If two dimensions of the cavity are bigger than the diameter of the holes used to create the cavity, then the cavity can support electromagnetic waves that cannot propagate through the holes, leading to a long lifetime in the cavity. A superconducting qubit or other non-linear element can be inserted into the cavity, which can controllably interact with each of several modes of the cavity. In this way, the modes of the cavity can act as components in a quantum memory.

Abstract: The present invention relates to a compound having a structure according to formula (I) or a salt thereof, wherein: R1 is a branched or linear alkyl, acyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, or hydroxy-alkinyl residue comprising 6 to 30 carbon atoms, R2 is selected from the group consisting of: a) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal or cyclic quaternary ammonium, b) an alkyl residue comprising 1 to 10 carbon atoms and comprising a terminal amino group and/or 1 to 3 hydroxyl groups, c) an amino acid residue, d) a five or six carbon sugar and e) H, R3 is a residue selected from the group consisting of an alkyl, alkenyl, prostanyl-dialkyl, furanyl-dialkyl, cyclobutyl-dialkyl, cycloalkyl and aryl group of 2 to 40 carbon atoms length and comprising at least one keto group, epoxy group, aldehyde group, peroxy group, hydroperoxy group, hydroxyl group or a free carboxyl group, L1 is selected from the group consisting of O, NH, S, CH2, (aa), (bb), (cc), (dd), (ee), (ff), (gg)

Abstract: Metal-organic framework (MOFs) compositions based on post¬synthetic metalation of secondary building unit (SBU) terminal or bridging OH or OH2 groups with metal precursors or other post-synthetic manipulations are described. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations, including the regioselective boryiation and siiylation of benzyiic C—H bonds, the hydrogenation of aikenes, imines, carbonyls, nitroarenes, and heterocycles, hydroboration, hydrophosphination, and cyclization reactions. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

Abstract: In some embodiments, methods of killing tumor cells are provided. The methods may include contacting the tumor cell with a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective element and/or a capsid protein that binds a tumor-specific cell surface molecule. In another embodiment, methods of treating cancer are provided. The methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, wherein the pharmaceutical composition includes a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule.

Abstract: The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.

Abstract: This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.

Abstract: The disclosure relates to improved therapeutic methods for treating cancer patients. The methods include a method for treating cancer in a subject comprising administering an effective amount of a BACH1 inhibitor and an ETC inhibitor to the subject. Further aspects of the disclosure relate to a method for treating cancer in a subject comprising: administering a first therapeutic regimen comprising an ETC inhibitor to the subject after a biological sample from the subject was determined to have a decreased or substantially the same level of expression of BACH1 relative to a control sample or to a cut-off value; wherein the first therapeutic regimen excludes a BACH1 inhibitor; or administering a second therapeutic regimen comprising a BACH1 inhibitor and an ETC inhibitor to the subject after a biological sample from the subject was determined to have an increased level of expression of BACH1 relative to a control sample or a cut-off value.

Abstract: Methods and systems are disclosed for sensing an environment electric field. In one exemplary implementation, a method includes disposing a sensor in the environment, wherein the sensor comprising a crystalline lattice and at least one optically-active defect in the crystalline lattice; pre-exciting the crystalline lattice to prepare at least one defect in a first charge state using a first optical beam at a first optical wavelength; converting at least one defect from the first charge state to a second charge state using a second optical beam at a second optical wavelength; monitoring a characteristics of photoluminescence emitted from the defect during or after the conversion of the at least one defect from the first charge state to the second charge state; and determining a characteristics of the electric field in the environment according to the monitored characteristics of the photoluminescence.